2012
DOI: 10.2337/dc11-2289
|View full text |Cite
|
Sign up to set email alerts
|

Effects of Gastric Bypass Surgery in Patients With Type 2 Diabetes and Only Mild Obesity

Abstract: OBJECTIVERoux-en-Y gastric bypass (RYGB) ameliorates type 2 diabetes in severely obese patients through mechanisms beyond just weight loss, and it may benefit less obese diabetic patients. We determined the long-term impact of RYGB on patients with diabetes and only class I obesity.RESEARCH DESIGN AND METHODSSixty-six consecutively selected diabetic patients with BMI 30–35 kg/m2 underwent RYGB in a tertiary-care hospital and were prospectively studied for up to 6 years (median 5 years [range 1–6]), with 100% f… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

5
125
0
10

Year Published

2013
2013
2017
2017

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 265 publications
(140 citation statements)
references
References 37 publications
5
125
0
10
Order By: Relevance
“…However, the median disease-free period among such individuals with Rouxen-Y gastric bypass (RYGB) is 8.3 years (52,56). With or without diabetes relapse, the large majority of patients who undergo surgery maintain substantial improvement of glycemic control from baseline for at least 5 (LoE IB) (20) to 15 (LoE IIA) (52,(55)(56)(57)(58)(59) years.…”
Section: Summary Of Evidence: Clinical and Biological Rationale For Smentioning
confidence: 99%
See 1 more Smart Citation
“…However, the median disease-free period among such individuals with Rouxen-Y gastric bypass (RYGB) is 8.3 years (52,56). With or without diabetes relapse, the large majority of patients who undergo surgery maintain substantial improvement of glycemic control from baseline for at least 5 (LoE IB) (20) to 15 (LoE IIA) (52,(55)(56)(57)(58)(59) years.…”
Section: Summary Of Evidence: Clinical and Biological Rationale For Smentioning
confidence: 99%
“…Beyond inducing weight loss-related metabolic improvements, some operations engage mechanisms that improve glucose homeostasis independent of weight loss (6), such as changes in gut hormones, bile acid metabolism, microbiota, intestinal glucose metabolism, and nutrient sensing (5,6,(26)(27)(28)(29)(30)(31)(32)(33)(34). Bariatric/ metabolic surgery confers sustained favorable effects on glycemiadup to 20 years in one observational study (52)dalthough benefits can decrease over time, with or without weight regain (3,51,52,(54)(55)(56).…”
Section: Summary Of Evidence: Clinical and Biological Rationale For Smentioning
confidence: 99%
“…However, this appears unlikely because bariatric surgery, particularly Roux-en-Y gastric bypass (RYGB) (Saeidi et al 2013), which is the most effective therapy for obesity and T2D (Carlsson et al 2012, Cummings 2012, increases blood GLP2 (by 200%) at postprandial status (le Roux et al 2010). Bariatric surgery normalizes blood glucose concentrations in the majority of T2D humans independent of weight loss (Mingrone et al 2012, Schauer et al 2012) and can induce diabetes remission up to 6 years (Cohen et al 2012). It is likely that the enhancement of nutrient flux into the distal small intestine after bariatric surgery triggers a signal leading to an antidiabetic effect that does not appear related to gastric inhibitory peptide (GIP) or GLP1 (Breen et al 2013).…”
Section: Glp2 and Glycaemic Controlmentioning
confidence: 99%
“…However, the median disease-free period among such individuals following Roux-en-Y gastric bypass (RYGB) is 8.3 years (52,53). With or without diabetes relapse, the majority of patients who undergo surgery maintain substantial improvement of glycemic control from baseline for at least 5 (54,55) to 15 (38,39,53,(56)(57)(58) years.…”
mentioning
confidence: 99%